Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sorting nexin-33 (SNX33) is a cytoplasmic protein involved in the reorganization of the cytoskeleton, vesicle trafficking, and endocytosis, particularly during mitosis and cytokinesis[1][3][7]. It contains PX, SH3, and BAR domains, enabling it to bind phosphatidylinositol lipids, interact with protein partners such as WASL and dynamins, and promote membrane remodeling. SNX33 is also implicated in modulating the endocytosis and secretion of specific cell-surface proteins, including the amyloid precursor protein (APP) and cellular prion protein (PRNP)[1][7]. The protein plays a key role in the formation of the cleavage furrow during cell division, and its dysfunction may perturb membrane trafficking processes. As of current knowledge, SNX33 is not considered a direct therapeutic target nor is it established as a clinical biomarker or drug target[1][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sorting nexin-33 (SNX33).